Relay Therapeutics, Inc. (RLAY) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Relay Therapeutics is a clinical-stage precision medicine company utilizing its Dynamo® platform to discover small molecule therapeutics for oncology and genetic diseases. The company has no products approved for commercial sale and has not generated revenue from product sales. Its lead product candidate, RLY-2608 (a PI3Kα inhibitor), is in clinical development for breast cancer and vascular malformations.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $0.7 million | $0 | $8.4 million | $10.0 million |
| Net Loss | $(70.4) million | $(92.2) million | $(147.4) million | $(173.6) million |
| Net Loss Per Share | $(0.41) | $(0.69) | $(0.87) | $(1.32) |
| R&D Expenses | $63.9 million | $92.0 million | $137.7 million | $174.4 million |
| G&A Expenses | $13.6 million | $20.1 million | $32.4 million | $39.9 million |
| Cash & Investments | $656.8 million (as of June 30, 2025) | |||
| Accumulated Deficit | $1.9 billion (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Shift: Revenue in Q2 2025 ($0.7 million) was derived entirely from the Elevar Therapeutics agreement (lirafugratinib). This contrasts with Q2 2024, which had no revenue. The Genentech collaboration agreement was terminated without cause effective January 7, 2025, ending future milestone payments from that partner.
- Expense Reduction: Total operating expenses decreased by approximately $23.2 million in Q2 2025 compared to Q2 2024. This reduction is attributed to strategic streamlining of the research organization (including the involuntary termination of approximately 70 employees) and cost avoidance following the Elevar licensing deal.
- Non-Cash Adjustments: The company recorded a $2.3 million impairment charge for an intangible asset (assembled workforce) related to the ZebiAI acquisition due to the aforementioned employee terminations. There was no change in the fair value of contingent consideration liability in 2025, whereas 2024 included a $11.4 million gain from such changes.
- Liquidity: Cash, cash equivalents, and investments decreased from $871.3 million at year-end 2024 to $656.8 million at June 30, 2025, primarily due to operating cash burn and lease termination/relocation payments.
Guidance, Outlook, and Risks
- Clinical Outlook: The company is preparing to initiate a global Phase 3 trial (ReDiscover-2) for RLY-2608 in mid-2025. Interim data from the ReDiscover trial showed a median progression-free survival of 10.3 months overall and 11.0 months in second-line patients.
- Liquidity Runway: Management believes existing cash and investments ($656.8 million) are sufficient to fund operations and capital expenditures into 2029.
- Key Risks:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will need to raise additional capital to achieve profitability.
- Clinical Uncertainty: No large-scale pivotal trials have been successfully completed; future trials may fail or be delayed.
- Collaboration Dependency: Reliance on third parties for clinical trials and manufacturing. The termination of the Genentech agreement highlights the risk of losing revenue streams from partners.
- Intellectual Property: Disputes regarding IP ownership with collaborators (e.g., D.E. Shaw Research) could impact development.
- Management Changes: Brian Adams resigned as Chief Legal Officer and Secretary effective August 8, 2025.
Investor Verification Checklist
- Runway Validation: Verify the $656.8 million cash balance and the assumptions underpinning the "into 2029" funding estimate, given the high burn rate.
- Phase 3 Timeline: Confirm the specific start date and enrollment targets for the ReDiscover-2 Phase 3 trial scheduled for mid-2025.
- Elevar Agreement Terms: Review the specific milestones and royalty structures in the Elevar Therapeutics agreement to understand future revenue potential.
- Restructuring Costs: Assess if the $2.3 million impairment and lease termination costs ($2.5 million payment) represent one-time charges or the beginning of ongoing facility/organizational costs.
- IP Status: Monitor the status of the D.E. Shaw Research collaboration (DESRES Agreement), which expires August 16, 2025, and its impact on the pipeline.